YOLFTbeta
ROKIT Healthcare Inc.

ROKIT Healthcare Inc.

376900 · KQ · Healthcare / Medical Care Facilities

17,250.00KRW-510.00 (-2.87%)

Price History

Full chart

Market Stats

Previous Close17,760.00
Open18,000.00
Day Range17,210.00 – 18,370.00
52-Week Range24,200.00 – 153,800.00
Volume127.72K
Market Cap435.50B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
50-Day Avg30,117.00
200-Day Avg60,723.00

About

ROKIT Healthcare Inc., a biotechnology company, provides hyper-personalized organ regenerative healthcare solutions in South Korea. The company offers skin regeneration therapy for the treatment of diabetic foot ulcers; cartilage regeneration delivers hyper-personalized therapeutic solutions for osteoarthritis patients; and kidney regeneration, a hyper-personalized treatment for chronic kidney disease (CKD). It also provides bioprinters; bioinks; Huma Media, a human adult stem cell culture media; HumaTein, a human cell-derived whole extracellular matrix; EpiTem, a reconstructed human epidermis model; and anti-aging supplements, as well as operates a tissue bank. The company was formerly known as ROKIT Inc. and changed its name to ROKIT Healthcare Inc. in 2018. The company was incorporated in 2012 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Care Facilities
  • CEOMr. Seok-hwan Yoo
  • HeadquartersDigital-ro 10-gil 9, Seoul, South Korea, 08514, Korea
  • Websitehttps://rokithealthcare.com

Leadership

  • Mr. Seok-hwan YooChairman & CEO · b. 1957
  • Yong-gyu LeeVP & CFO · b. 1971
  • SangMin LeeExecutive Director · b. 1971

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue9.15B12.42B13.11B26.25B
Growth (%)-+35.70%+5.59%+100.19%
Cost of Revenue6.05B8.37B7.13B10.56B
Gross Profit3.10B4.05B5.98B15.69B
Gross Margin33.92%32.59%45.63%59.77%
Operating Expense16.98B11.41B11.55B15.24B
Operating Income-13.87B-7.36B-5.57B452.88M
Operating Margin-151.61%-59.31%-42.50%1.73%
EBITDA7.91B24.31B496.02M3.45B
EBITDA Margin86.39%195.75%3.78%13.15%
Net Income1.87B16.60B-7.65B-2.85B
Net Income Margin20.48%133.68%-58.31%-10.84%
R&D2.98B1.77B1.57B1.02B
R&D as % of Total Revenue32.55%14.27%11.98%3.90%
Interest Expense4.50B6.21B6.85B4.57B
Interest Expense % of Total Revenue49.21%50.00%52.21%17.41%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets14.18B8.48B11.33B55.03B
Total Liabilities111.66B86.94B88.45B43.47B
Total Equity-97.46B-78.46B-77.07B11.56B
Cash3.56B965.29M3.01B31.05B
Net Debt5.40B10.21B11.57B-

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.59B-3.92B-5.00B-17.23B
Capital Expenditure216.69M296.34M195.70M536.27M
Free Cash Flow-6.80B-4.21B-5.20B-17.77B
FCF to OCF103.29%107.57%103.91%103.11%

Earnings

Report DateJun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----
EPS Actual-63.06-97.34-22.75-117.16-594.05
Surprise-----
Timing-----

Key Statistics & Ratios

Market Cap435.50B
Enterprise Value403.36B
Trailing P/E0.00
Forward P/E0.00
Price / Sales13.27
Price / Book65.13
Revenue (TTM)32.81B
Gross Profit (TTM)15.93B
EBITDA-14.62B
Profit Margin-38.67%
Operating Margin-163.75%
Return on Equity-64.43%
Return on Assets-14.62%
Shares Outstanding15.69M
Shares Float12.24M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%